Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Congratulations to Dr Erdinc Sezgin, who will be part of the prestigious SciLifeLab Fellowship programme and the Karolinska Institutet.

Formerly a member of the Eggeling lab at MRC HIU, Erdinc will lead the Cell Signalling, Immunity and Nanoimaging Lab (CSI:Nano), working on biophysical and physicochemical aspects of cell signalling using advanced technologies in imaging and synthetic biology.

The SciLifeLab Fellows program is a career program aimed at strengthening Swedish research in Molecular Biosciences and supporting a long-term societal impact. The Sezgin group is specifically hosted by the Karolinska Institutet. The host universities provide an advantageous economic starting package and together with SciLifeLab, a strong interdisciplinary research environment in close proximity to a cutting-edge research infrastructure.

SciLifeLab, Science for Life Laboratory, was founded in 2010 as a joint effort between four universities: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University. Today, they support research activities at all major Swedish universities.

We wish all the best to Erdinc in his future endeavours. More information about the Sezgin group can be found here.

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

Professor Graham Ogg elected Academy of Medical Sciences Fellow

Fellows are selected for their exceptional contributions to the advancement of medical science through innovative research discoveries and translating scientific developments into benefits for patients and the wider society.